The myopic focus of companies on profits has been criticized in recent years. Mads Øvlisen, the former CEO of @NovoNordisk, explains how the pursuit of a corporate purpose beyond short-term profits, can actually lead to higher long-term profits @TimaBansal forbes.com/sites/timabans…
Corporate purpose isn’t just about vision and values, it’s about keeping an eye on the long term. Upholding #corporate purpose requires leaders to resist the short-term demands of shareholders & investors in order to build good & successful companies #CSR forbes.com/sites/timabans…
In 1971 for the first time in Novo Nordisk’s history, #Øvlisen’s father-in-law had to make the decision to lay off employees. Faced with a similar challenge, Øvlisen worked hard to relocate them elsewhere in the organization, even if the fit wasn’t perfect
“I wanted us to be a company respected for our results and for the way in which we achieved the results. When people hear the name Novo, they’ll say, ‘Weren’t they the people that did something to improve diabetes, hiring conditions, and the environment?’
When Øvlisen became CEO, Novo had 21 competitors in the insulin market. He knew he had to offer a product better than his competitors’. For this reason, he invested heavily in R&D.
Novo was the first company to produce highly purified #insulin preparations forbes.com/sites/timabans…
CEO Mads Øvlisen inherited and left a pharma company that was built on a strong foundation –literally. The @novonordiskfond controls @novonordisk through Class A shares, yet divests all strategic and operational matters to Novo Nordisk’s Board of Directors forbes.com/sites/timabans…
Øvlisen also insisted on listening to one’s critics. When @WWF raised issues about the impact of @NovoNordisk’s activities on the environment, Øvlisen did not simply invite them for coffee and a Danish. Ultimately, the NGOs influenced Novo’s strategy #ESG forbes.com/sites/timabans…
It’s far too easy for corporate executives to lose sight of where they’re going. A corporate purpose is becoming an increasingly important north star, guiding a company to a destination of creating long-term value for both stakeholders & society as a whole forbes.com/sites/timabans…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Psychologist Dr. Lee-Anne Gray founded a school whose mission is “Empathic Education for a Compassionate Nation.” She teaches the art of empathic listening and it is a powerful technique to dismantle normalized bullying in our society @bulliedbrain#resist psychologytoday.com/ca/blog/the-bu…
Identifying with the aggressor is comparable to Stockholm syndrome, in which a hostage will bond with their captor. This bonding occurs because the brain is aware that the captor could harm or kill the #hostage. The bond intensifies as a survival strategy psychologytoday.com/ca/blog/the-bu…
@bulliedbrain's clients want to know why as employees, they suffered repeat abuses. To overcome this obstacle to recovery, we must first recognize how bullying works.
In 2018, @pfizer had turned to Kathrin and her research team to identify a partnership that would advance mRNA development for a game-changing seasonal flu vaccine. During the #partnership search, she made fast friends with the Turkish-German cofounder and BioNTech CEO Ugur Sahin
Pfizer signed a collaboration agreement to codevelop a first-in-class, mRNA-based coronavirus vaccine, aimed at preventing COVID-19 infection. BioNTech received $72 million up-front & was eligible for future milestone payments of an additional $563 million amazon.com/Moonshot-Pfize…
In addition, we were going to provide $113 million in cash to @BioNTech_Group by buying equity from the company. The two parties agreed to share all development costs and profits fifty-fifty. If the project failed, @pfizer would bear all the losses alone
@JeremyFarrar: (laughs) If I knew, I'd be a @NobelPrize candidate–or a multibillionaire...
It would be a once-in-a-lifetime vaccine like the one against measles,
it would cost a cent,
it would block transmission spiegel.de/international/…
Is it still possible to find a vaccine for this soup of different variants? @JeremyFarrar: We have to get ourselves out of that situation. And I think the only way we're going to get ourselves out of that is the generation of vaccines @bredow@VHackenbroch
How realistic is it that a perfect vaccine will materialize?
Farrar: Is it possible today? No, certainly not. Would it be possible this decade? Possibly not yet either.
If the political class moves on & pretend it's over, I fear, that investment won't come
We have tested the antibody in various doses on 856 patients on 3 continents. After only 6 months we observed positive results, and after 18 months 81% of the group receiving the highest dosage showed lower levels of amyloid beta than the level we measure in Alzheimer’s-Lannfelt
“The idea for the antibody originated back in the 1990s, when the team identified a change in the genetic material of a Swedish family that had been severely afflicted by Alzheimer's disease. The mutation indicated that the cause seemed to be protofibrils” medicalxpress.com/news/2018-10-a…
Overnight a Swedish professor made $350 million. The lucky man, Lars Lannfelt, was not particularly famous. He had done pioneering work on Alzheimer’s, but it was in the 90s and belonged to a sub-field that, after a litany of failures had fallen from grace statnews.com/2022/10/11/for…
The @StanfordDaily reached out to Science and @Nature, where another of Tessier-Lavigne’s papers containing alleged data alteration was published, for comment. @ScienceMagazine's editor-in-chief @hholdenthorp wrote in an email that he would “check around.”
Marc Tessier-Lavigne’s papers with issues confirmed by the University have accrued tens of thousands of downloads and include some of his most cited work in neurobiology. None of the papers has been retracted or corrected @tab_delete@StanfordDaily#scipol
Right now, we're going after the pathology of the disease–plaques & tangles-but I think we need to start going after the biology and, as a result, the pharmacology that addresses the altered biology with aging that occurs in Alzheimer's-@a_hfillit@TheADDF biospace.com/article/ctad-2…
“The mixed data shows that while anti-amyloids are a promising starting point, we will need a combination of drugs aimed at different targets informed by the biology of aging to effectively treat this disease”
-@a_hfillit, M.D., co-founder and CSO @TheADDF fiercebiotech.com/biotech/roche-…